Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients

Clinical and Experimental Immunology

Volumn 116, Issue 2, 1999, Pages 347-353

  Menegatti, E ^f   Roccatello, Dario ^b,e   Fadden, K ^d   Piccoli, G ^a   De Rosa, G ^c   Sena, L M ^f   Rifai, A ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b Divisione di Nefrologia e Dialisi   (Italy)

^c Servizio di Anatomia Patologica   (Italy)

^d RHODE ISLAND HOSPITAL   (United States)

^e Sede L Einaudi   (Italy)

^f NONE

Author keywords

5 lipoxygenase; Leukotrienes; LTA4 hydrolase; Nephrotic syndrome

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; HYDROLASE; LEUKOTRIENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY PARENCHYMA; LEYDIG CELL; MARKER GENE; NEPHROTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD19; ARACHIDONATE 5-LIPOXYGENASE; EPOXIDE HYDROLASES; GENE EXPRESSION; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; MIDDLE AGED; NEPHROTIC SYNDROME;

EID: 0032944901     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00858.x     Document Type: Article

References (28)

1. 1 Wehrmann M, Bohle A, Bogensch TZO et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. Clin Nephrol 1989; 31:67-76.
2. 2 Abe S, Amagasaki Y, iyori S, Konishi K, Kato E, Sagakuchi H. Significance of tubulointerstitial lesions in biopsy specimens of glomerulonephritic patients. Am J Nephrol 1989; 9:30-37.
3. 3 Wang H, Tomino Y, Fukui M et al. Correlation between tubulointerstitial changes and prognosis in patients with primary membranous nephropathy. Nephron 1994; 67:362.
4. 4 Salant DJ, Quigg RJ, Cybulsky AV. Heymann nephritis: mechanism of renal injury. Kidney Int 1989; 35:976-84.
5. 5 Gabbai FB, Gushwa LC, Wilson CB, Blantz RC. An evaluation of the development of experimental membranous nephropathy. Kidney Int 1987; 31:1267-78.
6. 6 Yoshioka T, Rennke HG, Salant DJ, Deen MW, Ichikawa I, Role of abnormally high transmurul pressure in the permselectivity defect on glomerular capillary wall: a study in early passive Heymann nephritis. Circ Res 1987; 61:531-8.
7. 7 Badr KF. Glomerulonephritis: roles for lipoxygenase pathways in pathophysiology and therapy. Curr Opin Nephrol Hypertens 1997; 6:111-8.
8. 8 Lianos EA, Noble B, Hucke B. Glomerular leukotriene synthesis in Heymann nephritis. Kidney Int 1989; 36:998-1002.
9. 4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis. J Clin Invest 1993; 91:1507-15.
10. 10 Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990; 323:645-53.
11. 11 Glasser RJ, Velosa JA, Michael AF. Experimental model of focal sclerosis. Lab Invest 1977; 36:519.
12. 12 Diamond JR, Pesek I, Ruggieri S, Karnowsky MJ. Essential fatty acid deficiency during acute puromycin nephrosis ameliorates late renal injury. Am J Physiol 1989; 257:F798-807.
13. 13 Harris KP, Lefkowith JB, Klahr S, Schreiner GF. Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after the administration of the aminonucleoside of puromycin. J Clin Invest 1990; 86:1115-23.
14. 14 Lefkowith JB, Klahr S. Polyunsaturated fatty acids and renal disease. Proc Soc Exp Biol Med 1996; 213:13-23.
15. 15 Funk CD, Fitzgerald GA. Eicosanoid forming enzyme mRNA in human tissues. J Biol Chem 1991; 266:12508-13.
16. 16 Rifai A, Sakai H, Yagame M. Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis. Kidney Int 1993; 43 (S39):S-95-S-99.
17. 17 Tauxe WN, Dubovsky EV, Kidd T. New formulae for the calculation of effective renal plasma flow by the single plasma sample method. Eur J Nucl Med 1982; 7:51-54.
18. 4 hydrolase/aminopeptidase by captopril. J Biol Chem 1991; 266:16507-11.
19. 4 in the rat. Circ Res 1984; 54:492-9.
20. 4 on glomerular dynamics in the rat. Am J Physiol 1987; 253:F239-43.
21. 4. Biochem Biophys Res Comm 1991; 178:302-8.
22. 22 Jakobsson P-J, Steinhilber D, Odlander B, Radmark O, Claesson H-E, Samuelsson B. On the expression and regulation of 5-lipoxygenase in human lymphocytes. Proc Natl Acad Sci USA 1992; 89:3521-5.
23. 23 Yee J, Kuncio GS, Neilson EG. Tubulointerstitial injury following glomerulonephritis. Semin Nephrol 1991; 11:361-6.
24. 24 Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20:1 -17.
25. 25 Spurney RF, Ruiz P, Pisetsky DS, Coffman TM. Enhanced renal leukotriene production in murine lupus: role of lipoxygenase metabolites. Kidney Int 1991; 39:95-102.
26. 20 de Caterina R, Caprioli R, Giannessi D et al. n-3 fatty acids reduce protein-uria in patients with chronic glomemlar disease. Kidney Int 1993; 44:843-50.
27. 27 de Caterina R, Endres S, Kristensen SD, Schmidt EB. n-3 fatty acids in renal diseases. Am J Kidney Dis 1994; 24:397-415.
28. 28 Guasch A, Zayas CF, Badr KF. Therapeutic effect of leukotriene biosynthesis inhibition in proliferative glomerulonephritis: results of the first human trial. J Am Soc Nephrol 1996; 1334.